COMPARISON OF OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL IN SEROUS ENDOMETRIAL CANCER AND UTERINE CARCINOSARCOMA

Yıl 2019, Cilt: 82 Sayı: 1, 1 - 4, 28.03.2019

Alpaslan Kaban Samet Topuz Hamdullah Sozen Yavuz Salihoglu

Öz

Objective: The aim of this study was to compare the survival durations of patients with uterine carcinosarcoma with the survival of patients with serous endometrial cancer.

Method: Patients who were operated for endometrial cancer between 2002 and 2014 were screened from clinic archive. Patients with histological tumor type carcinosarcoma or serous type were included in the study.

Results: Total number of patients was 99; 53 of them had carcinosarcoma and 46 had serous histology. Median disease-free survival was 20 (2-27) months in carcinosarcoma and 36 (3-180) months in serous type (Log-Rank test p=0.156). Median overall survival duration was 28 (4-170) months for carcinosarcoma and 46 (3-180) months for serous (p=0.105). The 5-year overall survival rate was 41.2% in carcinosarcoma histology and 55.4% in serous histology. After recurrence, patients with carcinosarcoma histology survived for an average of 8 (1-19) months, while those with serous histology survived for an average of 14 (2-43) months (p=0.090).

Conclusion: According to the results of Log-Rank test analysis, no statistically significant survival difference between the patients with uterin carcinosarcoma and with serous endometrial cancer was found. However, disease-free survival, overall survival, and survival duration after recurrence are longer in serous histology than in carcinosarcoma.

Anahtar Kelimeler

Endometrium cancer, survival, carcinoma, carcinosarcoma

SERÖZ ENDOMETRİAL KANSER VE UTERİN KARSİNOSARKOMDA GENEL SAĞKALIM VE HASTALIKSIZ SAĞKALIMIN KARŞILAŞTIRILMASI

Öz

Amaç: Bu çalışmanın amacı uterin karsinosarkomlu hastaların yaşam süresini, seröz endometrial kanserli hastaların yaşam süreleri ile karşılaştırmaktı.

Yöntem: 2002-2014 yılları arasında endometriyal kanser nedeniyle opere edilen hastalar klinik arşivinden tarandı. Çalışmaya histolojik tümör tipi karsinosarkom veya seröz tip olan hastalar dahil edildi.

Bulgular: Toplam hasta sayısı 99; bunların 53’ünde karsinosarkom, 46’sında seröz histoloji saptandı. Medyan hastalıksız sağkalım süresi karsinosarkomda 20 (2-27) ay ve seröz tipte 36 (3-180) aydı (Log-Rank testi p=0,156). Medyan sağkalım süresi karsinosarkom için 28 (4-170) ay, seröz için 46 (3-180) aydı (p=0,105). Beş yıllık genel sağkalım oranı, karsinosarkom histolojisinde %41,2 iken, seröz histolojide %55,4 idi. Nüksten sonra, karsinosarkom histolojisi olan hastalar ortalama 8 (1-19) ay, seröz histolojisi olanlar ortalama 14 (2-43 ay) yaşamışlardı (p=0,090).

Sonuç: Log-Rank test analizi sonuçlarına göre, uterin karsinosarkomlu ve seröz endometriyal kanserli hastalar arasında istatistiksel olarak anlamlı bir sağkalım farkı bulunmadı. Bununla birlikte, hastalıksız sağkalım, genel sağkalım ve nüks sonrası sağkalım süresi seröz histolojide karsinosarkomdan daha uzundur.

Anahtar Kelimeler

Endometrium kanseri, sağkalım, karsinom, karsinosarkom

Kaynakça

• 1. Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol 2011;54(2):278–91.
• 2. Ferrandina G, Zannoni GF, Martinelli E, Vellone V, Prisco MG, Scambia G. Endometrial carcinoma recurring as carcinosarcoma: Report of two cases. Pathol Res Pract 2007;203(9):677–81.
• 3. NCCN. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Nccn. 2015; https://www.nccn.org/professionals/physician_gls/default.aspx
• 4. Spaziani E, Picchio M, Petrozza V, Briganti M, Ceci F, Di Filippo A, et al. Carcinosarcoma of the uterus: A case report and review of the literature. Eur J Gynaecol Oncol 2008;29(5):531–4.
• 5. Singh R. Review literature on uterine carcinosarcoma. J Cancer Res Ther 2014;10(3):461–8.
• 6. Zhang C, Hu W, Jia N, Li Q, Hua K, Tao X, et al. Uterine carcinosarcoma and high-risk endometrial carcinomas: A clinicopathological comparison. Int J Gynecol cancer 2015;25(30973185):629–36.
• 7. Piver MS, Lele SB, Marchetti DL, Emrich LJ. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. J Surg Oncol 1988;38(4):233–9.
• 8. Gadducci A, Fabrini MG, Facchini V, Ducci F, Colosimo S, Dell’Arciprete T, et al. Surgery and radiotherapy in the treatment of early stage uterine sarcomas. Eur J Gynaecol Oncol 1989;10(4):276–80.
• 9. Hamilton C, Cheung M, Osann K, Chen L, Teng N, Longacre T, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94(5):642–6.
• 10. Üreyen I, Karalok A, Cırık DA, Taşçı T, Türkmen O, Cömert GK, et al. A comparison of clinico-pathologic characteristics of patients with serous and clear cell carcinoma of the uterus. Turk J Obs Gynecol 2016;13(3):137–43.
• 11. Felix AS, Stone RA, Bowser R, Chivukula M, Edwards RP, Weissfeld JL, et al. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer 2011;21(5):877–84.